Related Experiment Videos
Neurobehavioral differences in superselective Wada testing with amobarbital versus lidocaine
Brian-Fred M Fitzsimmons1, Randolph S Marshall, John Pile-Spellman
1Cerebrovascular Center of the Neurological Institute, Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
AJNR. American Journal of Neuroradiology
|August 15, 2003
Summary
Lidocaine enhanced superselective Wada testing for cerebral arteriovenous malformations (AVMs). This method detected neurologic deficits missed by amobarbital alone, improving test accuracy for AVM patients.
Area of Science:
- Neurology
- Neurosurgery
- Radiology
Background:
- Cerebral arteriovenous malformations (AVMs) pose risks requiring precise pre-surgical evaluation.
- Superselective Wada testing is crucial for assessing functional brain deficits before AVM treatment.
Observation:
- Four patients with cerebral AVMs underwent Wada testing using both amobarbital and lidocaine.
- Lidocaine administration revealed significant neurologic deficits not identified by amobarbital alone.
Findings:
- Pharmacodynamic differences between amobarbital and lidocaine likely explain the varied detection of neurologic deficits.
- Lidocaine demonstrated superior sensitivity in identifying critical neurologic impairments during Wada testing.
Implications:
- Incorporating lidocaine into superselective Wada testing may enhance diagnostic accuracy for cerebral AVMs.
- This improved sensitivity could lead to better pre-embolization planning and patient outcomes.